Dr. Doherty's dissertation work from UC Davis in the lab of Dr. Peter Beal developed a chemical modification that is now part of the lead molecules in clinical trials directed by ProQR Therapeutics. "Recently, ProQR Therapeutics, a biotech company based in the Netherlands that Beal’s team works closely with, reported positive results from a Phase 1 study that used RNA-based editing to reduce toxic bile acid accumulation in the liver, an underlying driver of cholestatic liver

A new research lab begins long before the first experiment runs. It starts with questions, people, instruments, space, habits, and a shared sense of what is worth understanding. That process is beginning now for the Doherty Lab at Columbia University Biological Sciences. In January 2027, we will join a department with a long tradition of research, teaching, and training. For information on how to get involed, please see the "Join Us" tab.